UCB0107 (bepranemab)
Phase 1Active 0 watching 0 views this week๐ค Quiet
30
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Supranuclear Palsy
Conditions
Progressive Supranuclear Palsy
Trial Timeline
Nov 16, 2020 โ Dec 13, 2027
NCT ID
NCT04658199About UCB0107 (bepranemab)
UCB0107 (bepranemab) is a phase 1 stage product being developed by UCB for Progressive Supranuclear Palsy. The current trial status is active. This product is registered under clinical trial identifier NCT04658199. Target conditions include Progressive Supranuclear Palsy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04658199 | Phase 1 | Active |
Competing Products
20 competing products in Progressive Supranuclear Palsy